Article
Author: Wang, Tony J C ; Chang, Eric L ; McClelland Iii, Shearwood ; Chao, Samuel T ; Chang, Eric L. ; Milano, Michael T. ; Chiang, Veronica L.S. ; Shiue, Kevin ; Lehrer, Eric J. ; Knisely, Jonathan P.S. ; Pollom, Erqi L. ; Knisely, Jonathan P S ; McGranahan, Tresa M. ; Chundury, Anupama ; Milano, Michael T ; Lehrer, Eric J ; Tom, Martin C. ; Tom, Martin C ; Breen, William G. ; Breen, William G ; Palmer, Joshua D ; Palmer, Joshua D. ; Nagpal, Seema ; McGranahan, Tresa M ; McClelland III, Shearwood ; Chiang, Veronica L S ; Saeed, Hina ; Chao, Samuel T. ; Pollom, Erqi L ; Wang, Tony J.C.
The ARS brain committee recommends that vorasidenib may be appropriate for recurrent or residual IDH-mutant grade 2 oligodendroglioma or astrocytoma. Vorasidenib is usually not appropriate for completely resected grade 2 oligodendroglioma or astrocytoma, any grade 3 oligodendroglioma or astrocytoma, or combined with radiotherapy and/or chemotherapy for any grade 2-3 glioma.